A prospective study of postmenopausal hormone use and ovarian cancer risk.

A prospective study of postmenopausal hormone use and ovarian cancer risk. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A prospective study of postmenopausal hormone use and ovarian cancer risk. Abstract Text:

K N Danforth,S S Tworoger,J L Hecht,B A Rosner,G A Colditz,S E Hankinson,

The relationship between postmenopausal hormone use (PMH) and ovarian cancer risk is unclear, particularly for specific hormone formulations, but recent studies suggest that there is a positive association. We conducted a prospective observational study with 82,905 postmenopausal women, including 389 ovarian cancers, in the Nurses' Health Study from 1976 to 2002. Compared with never users of PMH, both current and past users of > or =5 years had a significantly elevated risk of ovarian cancer (RR=1.41, 95% confidence interval (CI) 1.07-1.86 and relative risk (RR)=1.52, 95% CI 1.01-2.27, respectively). Examined by hormone type in continuous years, use of unopposed estrogen was associated with a significant increase in the risk of epithelial ovarian cancer (P for trend <0.001; RR for 5-year increment of use=1.25, 95% CI 1.12-1.38). Use of estrogen plus progestin (RR for 5-year increment of use=1.04, 95% CI 0.82-1.32) was not significantly associated with ovarian cancer risk. Generally, results were similar for serous tumours (RR for 5-year increment of unopposed estrogen use=1.23, 95% CI 1.07-1.40) and slightly stronger for endometrioid tumours (RR for 5-year increment of unopposed estrogen use=1.53, 95% CI 1.20-1.94). Recency of use was not significantly associated with ovarian cancer risk, but statistical power was limited here.

A prospective study of postmenopausal hormone use and ovarian cancer risk. Publishing Authors By Initials

KN Danforth,SS Tworoger,JL Hecht,BA Rosner,GA Colditz,SE Hankinson,

For similar investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research abstracts see: investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research

PUBMED ID PMID:

MEDLINE DATE:

A prospective study of postmenopausal hormone use and ovarian cancer risk. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: British journal of cancer

VOLUME: 96

Page Numbers: 151-6

Journal Abbreviation: Br. J. Cancer

ISSN: 0007-0920

DAY: 19

MONTH: 12

YEAR: 2006

A prospective study of postmenopausal hormone use and ovarian cancer risk. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370635

A prospective study of postmenopausal hormone use and ovarian cancer risk. Keywords Mesh Terms:

KEYWORDS: Risk Factors

MESH TERMS: adverse effects

Chemical & Substance for Abstract: A prospective study of postmenopausal hormone use and ovarian cancer risk. Information

Substance Name: Progestins

Registry Number: 0

Grant and Affiliation Information for A prospective study of postmenopausal hormone use and ovarian cancer risk.

AFFILIATION: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. kim.danforth@channing.harvard.edu

Country: England

AGENCY: United States NCI

GRANT: CA87969

ACRONYM: CA

MEDLINETA: Br J Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A prospective study of postmenopausal hormone use and ovarian cancer risk Related Publications

• A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia.
• A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer.
• A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
• A prospective study of postmenopausal hormone use and ovarian cancer risk.
• Aspirin, NSAID, and Acetaminophen Use and the Risk of Endometrial Cancer.
• Association of activity and chronic disease risk factors: utility and limitations of objectively measured physical activity data.
• Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.
• Birthweight and body size throughout life in relation to sex hormones and prolactin concentrations in premenopausal women.
• Body shape throughout life and correlations with IGFs and GH.
• Breastfeeding and risk of ovarian cancer in two prospective cohorts.
• Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer.
• Circulating colony stimulating factor-1 and breast cancer risk.
• Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.
• Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer.
• Dietary patterns, the Alternate Healthy Eating Index and plasma sex hormone concentrations in postmenopausal women.
• Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.
• Identification of novel dioxin-responsive genes by representational difference analysis.
• Identifying target genes of the aryl hydrocarbon receptor nuclear translocator (Arnt) using DNA microarray analysis.
• Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts.
• Menopausal and reproductive factors and risk of age-related macular degeneration.
• Physical activity and inactivity in relation to sex hormone, prolactin, and insulin-like growth factor concentrations in premenopausal women - exercise and premenopausal hormones.
• Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer.
• Plasma adiponectin concentrations and risk of incident breast cancer.
• Plasma androgen concentrations and risk of incident ovarian cancer.
• Prolactin and breast cancer risk.
• Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels.
• Reproducibility of proteomic profiles over 3 years in postmenopausal women not taking postmenopausal hormones.
• The role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon receptor action.
• Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis.
• Why does ARNT2 behave differently from ARNT?